Business Wire

Sigfox and INDIGO® weel Join Forces to Promote 100% Connected Urban Mobility

Share

Self-service bicycle fleet INDIGO® weel, a subsidiary of the INDIGO group, has been fitted with sensors, supported by Sigfox's 0G network, that can accurately pinpoint their location at any given time. As the number of shared vehicles in circulation increases, this integration of Sigfox technology will help to better protect the fleet from damage or theft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190712005234/en/

Photo : INDIGO weel

Photo : INDIGO weel

The Sigfox solution offers multiple benefits for INDIGO® weel:

  • An easier customer journey: pinpointing the location of bicycles more accurately, in real-time, allows users of the service to locate bikes on the street faster and more easily;
  • Better protection against damage and theft due to a greater understanding of high-risk areas;
  • A reduction in repair costs thanks to reusable sensors that can easily be transferred from a damaged bike to a new one;
  • Flexible technology that can be used in other markets, if the INDIGO® weel service expands internationally, courtesy of Sigfox's global 0G network that spans some sixty countries;
  • Durable sensors that consume very little energy

Together, INDIGO® weel and Sigfox are providing a solution to the public that addresses a number of the current challenges facing mobility services. Population growth in cities, as well as increasing environmental awareness now requires us to reconsider the way we move around each day. Innovative private sector services are therefore needed, in order to be able to offer a wider range of mobility solutions to the public. These must, however, complement the existing public transport offering, with those in charge working closely with city authorities in metropolitan areas.

New mobility solutions have been changing the face of city centre travel in recent years, but in order to be fully effective, they still have to find their place in the landscape. In this new market, INDIGO® weel is positioning itself as an innovative brand, keen to constantly evolve and partner with other forward-thinking businesses to do that.

One example of this innovation prompts users to take a photo at the end of their bike rental period to certify that the vehicle is in good parking condition. Each photo is then processed by customer services and users who comply with national, local and ‘Our Service’ rules will gain access to more advantageous offers.

Any change involves some risks and challenges, but the association between Sigfox and INDIGO® weel is already reaping benefits. Since the fleet was equipped with connected sensors, improvements to the geolocation system has reduced bicycle damage by a factor of 4. In addition, bicycle repair/replacement is now also faster than in the past. These improvements benefit INDIGO® weel, but also, more broadly, the inhabitants of cities where the connected vehicles are available, providing them with a high quality, sustainable service.

Jean Gadrat, CEO of INDIGO® weel, explains: "Public stakeholders and users today want a wider range of mobility solutions at their disposal and innovation in the sector that will help shape the city of tomorrow. It is in this context that we enter the market as a private company, in order to provide citizens with a respectful, complementary offering. INDIGO® weel wants to be a responsible player in the urban mobility market. We work tirelessly to offer the best possible service to our customers and make our products more efficient, which is why we have chosen to embed Sigfox’s technology into the fleet. It allows us to strengthen the sustainability of our offering and fully integrate our vehicles into the urban ecosystem.”

Patrick Cason, General Manager at Sigfox France, said: "Through this collaboration, we are once again demonstrating the many ways in which our 0G network can be used to serve society. The challenges of mobility, especially in cities, are many and well known. Faced with increasingly populated cities and an environmental awareness that can no longer be ignored, we must create new, more sustainable mobility solutions. Free floating bike is one of them. We are working with INDIGO® weel to provide the best service possible to meet the needs of citizens and to ensure that free floating bike finds its place in the city.

About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.

Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.

Contact information

Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu